Revenue recognition reserve target exclusivity period. Revenue Recognition Reserve Target Exclusivity Period Revenue recognition, reserve target exclusivity period 2024 Lessee, Operating Lease, Liability, to be Paid, Year One Lessee Operating Lease Liability Payments Due Next Twelve Months, Total Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative Document Transition Report Document Transition Report Performance obligation Revenue, Remaining Performance Obligation, Amount Inventory, Cash Flow Policy [Policy Text Block] Restricted Cash Geographical [Axis] Geographical Accounting Standards Update 2014-09 [Member] ASC 606 [Member] Other Liabilities, Noncurrent Other non-current liabilities Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expense and other assets Increase (Decrease) in Prepaid Expense and Other Assets, Total Contra expense included in research and development expense. Contra Expense Included In Research And Development Expense Contra expense included in research and development expense Vinbiocare. Vinbiocare [Member] Vinbiocare [Member] Fair Value Disclosures [Text Block] Fair Value Measurements September two thousand and twenty one lease agreement. September Two Thousand And Twenty One Lease Agreement [Member] September 2021 Lease Agreement [Member] Revenue from Contract with Customer, Excluding Assessed Tax Revenue Total revenue Revenue from Contract with Customer, Excluding Assessed Tax, Total COVID-19 vaccine development. C O V I D Nineteen Vaccine Development [Member] COVID-19 Vaccine Development Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized Accrued liabilities paid upon occurrence of specified events Right-of-use assets Increase Decrease Operating Lease, Right Of Use Asset Increase decrease operating lease, right of use asset. Disaggregation of Revenue [Table Text Block] Schedule of Revenue Long-Term Debt [Member] Long-term Debt [Member] Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] Description of Business, Basis of Presentation and Summary of Significant Accounting Policies Billing received amount related to clinical trial. Billing Received Amount Related to Clinical Trial Billing received amount from third party related to clinical trial Share-Based Payment Arrangement, Cost by Plan [Table Text Block] Schedule of Share-based Compensation Expenses Subsequent Events [Text Block] Subsequent Events Collaboration Partner Cure Vac entered into Co-Development Agreement. Collaboration Partner Cure Vac Entered Into Co Development Agreement [Member] Collaboration Partner Cure Vac Entered Into Co Development Agreement [Member] Equity Method Investment, Nonconsolidated Investee [Axis] Equity Method Investment, Nonconsolidated Investee Royalty payment term description. Royalty Payment Term Description Royalty payment term description Operating Lease, Liability, Noncurrent Operating lease liability, net of current portion Schedule of Stock by Class [Table] Schedule Of Stock By Class [Table] Repyament of principal and interest on collateralized term loan Repyament of Principal and Interest on Collateralized Term Loan Repyament of principal and interest on collateralized term loan. Janssen. Janssen [Member] Janssen [Member] Class of Stock [Line Items] Class Of Stock [Line Items] Related Party Transactions [Abstract] Commitment and contingencies. Commitment And Contingencies [Line Items] Commitment And Contingencies [Line Items] Assets, Current Total current assets Liabilities and Equity Total liabilities and stockholders’ equity Entity Address, State or Province Entity Address, State or Province Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive loss Upfront payment including taxes. Upfront Payment Including Taxes Upfront payment including taxes Trading Symbol Trading Symbol Purchase of common stock, shares Common Stock, Shares, Issued, Total Issuance of Shares Common stock, shares issued Milestone payments. Milestone Payments Milestone payments Collaboration agreement contractual term. Collaboration Agreement Contractual Term Contractual term Upfront fee received. Upfront Fee Received Upfront fee received Additional financial support Additional financial support Additional financial support Loans interest rate, percentage Line of Credit Facility, Interest Rate During Period Liquidity. Liquidity Policy Policy [Text Block] Liquidity Issuance of common stock under equity plans Stock Issued During Period Value Under Equity Plan Stock issued during period value under equity plan. Borrowings under Guaranteed Investment Agreements Term loan draw down Schedule of Long-Term Debt Instruments [Table] Debt Instrument [Table] Shares, Outstanding Balance (in shares) Balance (in shares) 2026 Lessee, Operating Lease, Liability, to be Paid, Year Three Common Stock, Capital Shares Reserved for Future Issuance Common stock reserved for future issuance Potential Principal Repayments Of Debt Instrument. Potential Principal Repayments Of Debt Instrument Potential principal repayment of loan Long-Term Debt, Current Maturities Current portion of long-term debt Long-term Debt, Current Maturities, Total Entity Address, City or Town Entity Address, City or Town Related Party Transaction [Line Items] Related Party Transaction [Line Items] Long-Term Debt, Maturity, Remainder of Fiscal Year 2022 Operating Lease, Weighted Average Discount Rate, Percent Weighted-average discount rate Lessee, Operating Lease, Renewal Term Operating lease extended additional term Debt Disclosure [Text Block] Debt Property, Plant and Equipment [Table Text Block] Summary of Components of Property and Equipment, Net Debt Instrument, Date of First Required Payment Loan first principal payment extended maturity date Subsequent Event [Member] Subsequent Event Subsequent Event Type [Axis] Cystic Fibrosis Foundation Therapeutics, Inc. Cystic Fibrosis Foundation Therapeutics Inc [Member] Cystic Fibrosis Foundation [Member] Additional Paid-in Capital [Member] Additional Paid-In Capital [Member] Debt Instrument, Collateral Debt instrument, collateral CSL Collaboration Agreement [Member] CSL Collaboration Agreement [Member] CSL Collaboration Agreement. Liabilities, Current [Abstract] Current liabilities: Assets, Current [Abstract] Current assets: Counterparty Name [Axis] Counterparty Name Statement of Stockholders' Equity [Abstract] Operating Lease, Liability, Current Current portion of operating lease liability Debt Instrument, Maturity Date Loan maturity date Long-Term Debt Long-term debt Total Financial grants received from the Japanese government Grants Received From Japanese Government Grants received from japanese government. Property, Plant and Equipment, Net Property and equipment, net Property and equipment, net Property, Plant and Equipment, Net, Beginning Balance Property, Plant and Equipment, Net, Ending Balance Payments for matching funds for remaining budgeted costs. Payments For Matching Funds For Remaining Budgeted Costs Payments for matching funds for remaining budgeted costs Statement of Comprehensive Income [Abstract] Scenario [Domain] Scenario Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative Entity Central Index Key Entity Central Index Key Class of Warrant or Right, Number of Securities Called by Warrants or Rights Exercise of warrants for shares of common stock Plan Name [Domain] Plan Name Restricted Cash, Noncurrent Non-current restricted cash Non-current restricted cash Lessee, Operating Lease, Option to Extend Lessee, operating leases, option to extend February two thousand and twenty lease agreement. February Two Thousand And Twenty Lease Agreement [Member] February 2020 Lease Agreement [Member] Revenue [Line Items] Revenue [Line Items] Revenue. Remainning research period Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period Milestone achievement. Milestone Achievement Milestone achieved Liabilities, Current Total current liabilities Entity Tax Identification Number Entity Tax Identification Number Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Net loss before income taxes Changes in assets and liabilities Increase (Decrease) in Operating Capital [Abstract] Disbursement period three. Disbursement Period Three [Member] Disbursement Due July 2020 [Member] Grant Revenue [Member] Grant [Member] Investment, Name [Axis] Investment, Name Term of agreement Debt Instrument, Term Reserved upfront payment Reserved Upfront Payment Reserved upfront payment. Construction in Progress [Member] Construction in progress [Member] Award Type [Axis] Award Type Plan Name [Axis] Plan Name Research Collaboration and Exclusive License Agreement. Research Collaboration And Exclusive License Agreement [Member] Research Collaboration And Exclusive License Agreement [Member] Equity Method Investment, Nonconsolidated Investee [Domain] Equity Method Investment, Nonconsolidated Investee Geographical [Domain] Geographical Lessee, Operating Lease, Term of Contract Lessee, operating lease, term of contract Assets Total assets BARDA [Member] Biomedical Advanced Research and Development Authority [Member] Biomedical Advanced Research and Development Authority. Operating Lease, Right-of-Use Asset Operating lease right-of-use asset, net Entity Registrant Name Entity Registrant Name Related Party, Type [Domain] Related Party Retained Earnings (Accumulated Deficit) Accumulated deficit Accumulated deficit Retained Earnings (Accumulated Deficit), Total Retained Earnings (Accumulated Deficit), Beginning Balance Retained Earnings (Accumulated Deficit), Ending Balance Proceeds from Stock Plans Proceeds from the issuance of common stock under equity plans Supplemental Cash Flow Information [Abstract] Supplemental disclosure of cash flow information Retained Earnings [Member] Accumulated Deficit [Member] Wells Fargo Credit Agreement [Member] Wells fargo credit agreement. Wells Fargo Credit Agreement [Member] Minimum [Member] Minimum [Member] Maximum sales required for loans forgivable . Maximum Sales Required For Loans Forgivable Maximum LUNAR-COVID 19 sales required for Loans forgivable Loan and security agreement. Loan And Security Agreement [Member] Loan and Security Agreement [Member] Proceeds from Stock Options Exercised Proceeds from exercise of stock options Operating Lease, Liability Total operating lease liabilities Operating Lease, Liability, Total Revenue [Policy Text Block] Revenue Recognition Equity Component [Domain] Equity Component Employee Stock Option [Member] Stock Option [Member] Adjustments to reconcile net loss to net cash provided by (used in) operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Prepayment fee percentage. Prepayment Fee Percentage Prepayment fee percentage Debt Disclosure [Abstract] Debt Instrument, Basis Spread on Variable Rate Interest of the prime rate plus Entity Current Reporting Status Entity Current Reporting Status Common Stock, Shares Authorized Common stock, shares authorized Research and Development Expense Research and development, net Research and Development Expense, Total Adjustments to transaction price. Adjustments To Transaction Price Adjustments to transaction price Assets [Abstract] Assets Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Number of shares available Ultragenyx. Ultragenyx [Member] Ultragenyx [Member] Common stock, $0.001 par value; 60,000 shares authorized; issued and outstanding shares were 26,723 at September 30, 2023 and 26,555 at December 31, 2022 Common Stock, Value, Issued Common Stock, Value, Issued, Total Common Stock, Value, Issued, Beginning Balance Common Stock, Value, Issued, Ending Balance Development and option agreement date. Development And Option Agreement Date Development and option agreement date Repayment of term loan Repayments of Long-Term Debt Repayments of Long-Term Debt, Total Foreign currency translation loss (gain) Realized Gain (Loss), Foreign Currency Transaction, before Tax Other Noncash Income (Expense) Other non-cash expenses Other Noncash Income (Expense), Total Additional payments upon meeting certain clinical milestones Additional Payments upon Meeting Certain Clinical Milestones Additional payments upon meeting certain clinical milestones. Deductions Contract with Customer, Liability, Revenue Recognized Deductions for promised services provided in current period Furniture and Fixtures [Member] Office equipment and furniture [Member] Accrued Liabilities, Current Accrued liabilities Total Current Fiscal Year End Date Current Fiscal Year End Date Share-Based Payment Arrangement, Noncash Expense Share-based compensation expense Share-based Payment Arrangement, Noncash Expense, Total Contra expense remaining amount included in accrued expenses. Contra Expense Remaining Amount Included In Accrued Expenses Contra expense remaining amount included in accrued expenses Operating Income (Loss) Loss from operations Repayments of Debt Payments on debt obligations Income tax expense Provision for income taxes Income Tax Expense (Benefit) Income Tax Expense (Benefit), Total Research and Development Expense [Member] Research and Development [Member] Stock Issued During Period, Shares, Acquisitions Issuance of common stock related to acquired in-process research and development (in shares) Lessee, Leases [Policy Text Block] Leases Share-Based Payment Arrangement, Expense Share-based compensation expenses Share-based compensation expenses Disaggregation of Revenue [Table] Disaggregation Of Revenue [Table] Equipment [Member] Research equipment [Member] Lease liabilities Increase (Decrease) in Operating Lease Liability Income tax payable Taxes Payable, Current Taxes Payable, Current, Total Clinical accruals current. Clinical Accruals Current Clinical accruals Revenue from Contract with Customer [Text Block] Revenue October 2017 lease amendment. October Two Thousand And Seventeen Lease Amendment [Member] October 2017 Lease Amendment [Member] Preclinical milestone payment received Preclinical Milestone Payment Received Preclinical milestone payment received. Summary of significant accounting policy. Summary Of Significant Accounting Policy [Line Items] Summary Of Significant Accounting Policy [Line Items] Debt Instrument, Face Amount Term loan Earnings Per Share, Policy [Policy Text Block] Net Loss per Share Western Alliance Bank. Western Alliance Bank [Member] Western Alliance Bank [Member] Finance income (expense), net Other Nonoperating Income (Expense) Other Nonoperating Income (Expense), Total Disbursement period two. Disbursement Period Two [Member] Disbursement Due April 2020 [Member] Contingent Grants [Member] Contingent grants member. Operating Expenses [Abstract] Operating expenses: Property, Plant and Equipment [Abstract] Long-Term Debt, Type [Domain] Long-term Debt, Type Depreciation, Depletion and Amortization, Nonproduction Depreciation and amortization Depreciation, Depletion and Amortization, Nonproduction, Total Subsequent Events [Abstract] COVID-19 vaccine. COVID-19 Vaccine [Member] COVID-19 Vaccine [Member] Other. Other [Member] Other Collaboration Revenue [Member] Commitments and Contingencies Disclosure [Abstract] Equity [Text Block] Stockholders' Equity Interest Paid, Excluding Capitalized Interest, Operating Activities Cash paid for interest Amount added under transaction price Addtional Amount Added Under Transaction Price Addtional amount added under transaction price. Additional Paid in Capital Additional paid-in capital Additional Paid in Capital, Total Additional Paid in Capital, Beginning Balance Additional Paid in Capital, Ending Balance Revenue recognition potential milestone revenue recognized. Revenue Recognition Potential Milestone Revenue Recognized Revenue recognition potential milestone revenue recognized Development milestones due Development Milestones Amount Due for Agreement Development milestones amount due for agreement. Equity, Attributable to Parent [Abstract] Stockholders’ equity Long-Term Contract with Customer [Member] Non-current Minimum incur amount under research plan Minimum Incur Amount Agreed Under Research Plan Minimum yncur amount agreed under research plan. 2021 Inducement equity incentive plan. Twenty Twenty One Inducement Equity Incentive Plan [Member] 2021 Inducement Equity Incentive Plan [Member] Eligible to Receive Development Milestone Payment Eligible to Receive Development Milestone Payment Eligible to receive development milestone payment Grant revenue Grant revenue. Grant revenue Lease Contractual Term [Domain] Lease Contractual Term Earnings Per Share [Abstract] Net loss per share: Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Remaining Payments of Operating Lease Liability Investment, Name [Domain] Investment, Name Accounting Policies [Abstract] Amount added to transaction price for achieving development milestone Amount Added to transaction Price for Achieving Development Milestones Amount added to transaction price for achieving development milestones. Development milestones received advance payment Development Milestones Received Advance Payment Development milestones received advance payment. Scenario [Axis] Scenario Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Loan accrued interest rate per annum, percentage Borrowings interest rate, percentage Debt Instrument, Interest Rate, Effective Percentage Basic Earnings Per Share, Basic Earnings Per Share, Basic, Total Number of reserved vaccine doses. Number Of Reserved Vaccine Doses Number of reserved vaccine doses Pre-launch inventory policy. Pre Launch Inventory Policy Policy [Text Block] Pre-Launch Inventory Payments for (Proceeds from) Tenant Allowance Tenant improvement allowance Related Party, Type [Axis] Related Party Summary of Changes in Balances of Receivables and Contract Liability Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Operating Lease, Cost Operating lease costs Statistical Measurement [Domain] Statistical Measurement Net Cash Provided by (Used in) Operating Activities Net cash provided by (used in) operating activities Proceeds from Issuance of Debt Net increase in indebtedness Proceeds from debt Upfront payment received. Upfront Payment Received Upfront payment received All Award Types Award Type Document Period End Date Document Period End Date Statistical Measurement [Axis] Statistical Measurement Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Stockholders' Equity Note [Abstract] Diluted Earnings Per Share, Diluted Earnings Per Share, Diluted, Total Product and Service [Domain] Product and Service Revenue [Table] Revenue [Table] Revenue. Revenue from Contract with Customer [Abstract] ADAIR Technology. A D A I R Technology [Member] ADAIR Technology [Member] February two thousand and twenty one lease agreement. February Two Thousand And Twenty One Lease Agreement [Member] February 2021 Lease Agreement [Member] Contra research and development expense. Contra Research And Development Expense Contra research and development expense recognized Research Collaboration And License Agreement [Member] Research collaboration and license agreement. Research Collaboration And License Agreement [Member] Number of performance obligations. Number Of Performance Obligations Number of performance obligations Schedule of Maturities of Long-Term Debt [Table Text Block] Schedule of Maturities of Long-term Debt Additions Contract With Customer Liability Additions Contract with customer liability additions. Foreign currency transaction gain (loss) Gain (Loss), Foreign Currency Transaction, before Tax Foreign Currency Transaction Gain (Loss), before Tax, Total Gain (loss) from foreign currency Development milestones amount received for agreement. Development Milestones Amount Received for Agreement Development milestones received Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Issuance of common stock upon exercise of stock options (in shares) Liabilities and Equity [Abstract] Liabilities and stockholders’ equity Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration] Operating Lease Liability Current Statement Of Financial Position [Extensible List] Agreement amount agreed to fund. Agreement Amount Agreed To Fund Amount agreed to fund Stock Issued During Period, Value, Acquisitions Issuance of common stock related to acquired in-process research and development Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Interactive Data Current Entity Interactive Data Current Private Placement [Member] Increase (Decrease) in Accounts Payable Accounts payable Increase (Decrease) in Accounts Payable, Total Lessee, Operating Lease, Liability, Undiscounted Excess Amount Less: imputed interest Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Grant one. Grant One [Member] Grant 1 Equity Components [Axis] Common Stock [Member] Increase (Decrease) in Accounts Receivable Accounts receivable CureVac AG. Cure Vac A G [Member] CureVac [Member] Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals Inc [Member] Alexion [Member] Local Phone Number Local Phone Number Property, Plant and Equipment [Line Items] Property Plant And Equipment [Line Items] Sale of Stock [Axis] Sale of Stock Grant revenue outstanding Grant revenue outstanding. Grant Revenue Outstanding Restricted Cash, Current Restricted cash Statement of Cash Flows [Abstract] Collateral amount Debt Instrument, Collateral Amount Debt instrument, collateral amount Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Vallon Pharmaceuticals, Inc. Vallon Pharmaceuticals Inc [Member] Vallon Pharmaceuticals, Inc. [Member] Common Stock, Par or Stated Value Per Share Common stock, par value SINGAPORE Singapore Economic Development Board [Member] Deferred Revenue, Noncurrent Deferred revenue, net of current portion Deferred Revenue, Noncurrent, Total Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Share-based compensation number of shares authorized Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Maximum [Member] Maximum [Member] Warrant fee payable. Warrant Fee Payable Warrant fee payable Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Comprehensive loss: Development milestones advance payment included in deferred revenue. Development Milestones Advance Payment Included in Deferred Revenue Development milestones advance payment included in deferred revenue Dividends Dividends declared or paid Dividends, Total Minimum amount agreed to incur under research plan Minimum Amount Agreed to Incur Under Research Plan Minimum amount agreed to incur under research plan. Monthly base rent. Monthly Base Rent Monthly base rent Debt Instrument, Increase, Accrued Interest Accrued interest added to principal debt balance APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Share-based compensation expense APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total Net decrease in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect General and Administrative Expense [Member] General and Administrative [Member] Other accrued research and development expenses. Other Accrued Research And Development Expenses Other accrued research and development expenses Grant Revenue Abstract. Grant Revenue [Abstract] Percentage required to be maintained in consolidated unrestricted cash. Percentage Required To Be Maintained In Consolidated Unrestricted Cash Percentage required to be maintain in consolidated, unrestricted cash City Area Code City Area Code Operating Activities Net Cash Provided by (Used in) Operating Activities [Abstract] Lessee operating lease liability payments due after year three. Lessee Operating Lease Liability Payments Due After Year Three Thereafter Proceeds from Issuance of Long-Term Debt Proceeds from long-term debt agreement Proceeds from Issuance of Long-term Debt, Total Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Less accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance General and Administrative Expense General and administrative General and Administrative Expense, Total Basic Weighted Average Number of Shares Outstanding, Basic Weighted Average Number of Shares Outstanding, Basic, Total Disbursement period four. Disbursement Period Four [Member] Disbursement Due October 2020 [Member] Financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Research and Development Costs, Net Research and Development Expense, Policy [Policy Text Block] Gain on debt extinguishment Gain on debt extinguishment Gain (Loss) on Extinguishment of Debt Gain (Loss) on Extinguishment of Debt, Total Statement [Table] Statement [Table] Schedule of Related Party Transactions, by Related Party [Table] Schedule Of Related Party Transactions By Related Party [Table] Increase (Decrease) in Contract with Customer, Liability Deferred revenue Document Fiscal Period Focus Document Fiscal Period Focus Lessee, Operating Lease, Liability, to be Paid Total remaining lease payments Additions Contract With Customer Asset Additions Contract with customer asset additions. Loss from equity-method investment Loss from equity-method investment Income (Loss) from Equity Method Investments Income (Loss) from Equity Method Investments, Total Option for renewal term Debt Instrument Option for Renewal Term Debt instrument option for renewal term. Related Party Transactions Disclosure [Text Block] Related Party Transactions 2025 Lessee, Operating Lease, Liability, to be Paid, Year Two Statement [Line Items] Statement [Line Items] Development milestones achieved. Development Milestones Achieved Development milestones achieved Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Antidilutive securities excluded from computation of earnings per share Accounts receivable, Balance Accounts receivable, Balance Contract with Customer, Asset, after Allowance for Credit Loss Contract with Customer, Asset, after Allowance for Credit Loss, Total The entire disclosure for grant revenue. Grant Revenue Disclosure [Text Block] Grant Revenue Remaining loan including accrued interest forgiveable Remaining Loan Including Accrued Interest Forgiveable Remaining loan including accrued interest forgiveable. Accounts Receivable, after Allowance for Credit Loss, Current Accounts receivable Accounts Receivable, after Allowance for Credit Loss, Current, Total Common Stock [Member] Common Stock [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value, Total Cash and Cash Equivalents, at Carrying Value, Beginning Balance Cash and Cash Equivalents, at Carrying Value, Ending Balance Grants Receivable Grant awarded Percentage of net profits. Percentage Of Net Profits Net profits percentage Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Vinbiocare agreement. Vinbiocare Agreement [Member] Vinbiocare Agreement [Member] Investment Owned, Balance, Shares Number of shares owned Cover [Abstract] Document Fiscal Year Focus Document Fiscal Year Focus Payments for Advance to Affiliate Payments for advance LUNAR-CF. L U N A R C F [Member] LUNAR-CF [Member] Notice period of termination. Notice Period Of Termination Notice period of termination Sale of Stock [Domain] Sale of Stock Reduction in number of common stock capital shares available for future issuance. Reduction in Number of Common Stock Capital Shares Available for Future Issuance Reduction in number of common stock shares available for future issuance Security Exchange Name Security Exchange Name Schedule of Cash and Cash Equivalents [Table Text Block] Schedule of Cash and Cash Equivalents and Restricted Cash Recently Issued Accounting Standards Not Yet Adopted New Accounting Pronouncements, Policy [Policy Text Block] Property, Plant and Equipment, Gross Property and equipment, gross Property, Plant and Equipment, Gross, Total Property, Plant and Equipment, Gross, Beginning Balance Property, Plant and Equipment, Gross, Ending Balance Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Right-of-use assets acquired through operating leases Phase I Clinical Study [Member] Phase I clinical study. Two thousand nineteen omnibus incentive plan. Two Thousand Nineteen Omnibus Incentive Plan [Member] 2019 Omnibus Equity Incentive Plan [Member] Weighted Average Number of Shares Outstanding, Diluted [Abstract] Weighted-average shares outstanding: Pharmaceutical company. Pharmaceutical Company [Member] Pharmaceutical Company [Member] Stock Issued During Period, Value, Stock Options Exercised Issuance of common stock upon exercise of stock options Entity Emerging Growth Company Entity Emerging Growth Company Amendment Flag Amendment Flag Eligible to receive commercial milestone payment. Eligible to Receive Commercial Milestone Payment Eligible to receive commercial milestone payment Schedule of Accrued Liabilities [Table Text Block] Schedule of Accrued Liabilities Israel Ministry of Health [Member] Israel Ministry of Health [Member] Israel ministry of health. Quarterly payments payable on terminations agreement. Quarterly Payments Payable On Terminations Agreement Total quarterly payments payable on terminations agreement Accounting Standards Update [Domain] Accounting Standards Update Basis of Accounting, Policy [Policy Text Block] Basis of Presentation Equity Method Investment, Ownership Percentage Equity method ownership percentage Amount drawn from Loan Proceeds from Lines of Credit Proceeds from Lines of Credit, Total Leases [Abstract] Additional payment payable on quarterly. Additional Payment Payable on Quarterly Quarterly payments payable Variable Rate [Domain] Securities Act File Number Entity File Number Unamortized Loan Commitment and Origination Fees and Unamortized Discounts or Premiums Loan origination fee paid Unamortized Loan Commitment and Origination Fees and Unamortized Discounts or Premiums, Total Study support agreement. Study Support Agreement [Member] Study Support Agreement 2023 Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Long-term debt Long-Term Debt, Excluding Current Maturities Long-Term Debt, Excluding Current Maturities, Total Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Cash, cash equivalents and restricted cash at end of the period Cash, cash equivalents and restricted cash at beginning of the period Total cash, cash equivalents and restricted cash shown in the statement of cash flows Cash and cash equivalents, including restricted cash and non-current restricted cash Balance Sheet Related Disclosures [Abstract] Share-Based Payment Arrangement [Abstract] Accounts Payable, Current Accounts payable Accounts Payable, Current, Total Deductions Contract With Customer Asset Deductions Contract with customer asset deductions. Operating Expenses Total operating expenses Long-Term Debt, Maturity, Year One 2023 Entity Address, Address Line Two Entity Address, Address Line Two Entity Small Business Entity Small Business Entity Shell Company Entity Shell Company Number of Operating Segments Number of operating segment for research and development Equity method investment, sale of common stock Sale of Stock, Number of Shares Issued in Transaction Class of Warrant or Right, Exercise Price of Warrants or Rights Share price Payment received first installment. Payment Received First Installment Received first installment Computer Equipment [Member] Computer and software [Member] Revenue: Revenues [Abstract] Entity Address, Address Line One Entity Address, Address Line One Contractual liabilities Contractual Obligation Contractual Obligation, Total Supplemental Balance Sheet Disclosures [Text Block] Balance Sheet Details Final payment of disbursement amount. Final Payment Of Disbursement Amount Final payment of disbursement amount Restricted Cash, Total Restricted Cash Restricted cash Non-refundable commitment fee, percentage Line of Credit Facility, Commitment Fee Percentage Subsequent Event Type [Domain] CSL Seqirus [Member] CSL Seqirus [Member] CSL seqirus. Income Statement Location [Axis] Income Statement Location Commitment and contingencies. Commitment And Contingencies [Table] Commitment And Contingencies [Table] Long-Term Debt, Type [Axis] Long-term Debt, Type Non-refundable payment received. Non Refundable Payment Received Non-refundable payment received mRNA technology. M R N A Technology [Member] mRNA Technology [Member] Product and Service [Axis] Product and Service Title of 12(b) Security Title of 12(b) Security Short-Term Contract with Customer [Member] Current Expected payment eligible to receive under agreement. Expected Payment Eligible to Receive Under Agreement Expected Payment Eligible To Receive Lease Contractual Term [Axis] Lease Contractual Term Accounting Standards Update [Axis] Accounting Standards Update Contract with Customer, Duration [Domain] Schedule of summary of significant accounting policies. Schedule Of Summary Of Significant Accounting Policies [Table] Schedule Of Summary Of Significant Accounting Policies [Table] Investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Arcalis, Inc. Arcalis, Inc [Member] The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer. as well as trade accounts receivable, notes and loans receivable. Prepaid Expenses And Other Receivables Prepaid expenses and other current assets Segment Reporting, Policy [Policy Text Block] Segment Information Agreement Termination Fee. Agreement Termination Fee Agreement termination costs Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset Deferred revenue, Balance Deferred revenue, Balance Contract with Customer, Liability Deferred revenue Contract with Customer, Liability, Total Business acquisition of holding share Business Acquisition Of Holding Share Business acquisition of holding share. Collaboration Revenue [Member] Collaboration Revenue [Member] Collaboration revenue. Royalty payment percentage. Royalty Payment Percentage Royalty payment percentage of proceeds from net sales Common Stock, Shares, Outstanding Common stock, shares outstanding Common Stock, Shares, Outstanding, Beginning Balance Common Stock, Shares, Outstanding, Ending Balance Share-Based Payment Arrangement [Text Block] Share-Based Compensation Expense Disbursed amount upon execution of amendment. Disbursed Amount Upon Execution Of Amendment Disbursed amount upon execution of amendment Underlying agreement. Underlying Agreement [Member] Underlying Agreement [Member] Income Statement Location [Domain] Income Statement Location Debt instrument interest only payment extended maturity date. Debt Instrument Interest Only Payment Extended Maturity Date Loan interest-only payment extended maturity date Contract with Customer, Duration [Axis] Document Type Document Type Fee payable Debt Instrument, Fee Amount Joint ventures, equity method investments and variable interest entities. Joint Ventures Equity Method Investments And Variable Interest Entities Policy [Text Block] Joint Ventures, Equity Method Investments and Variable Interest Entities Revenue, Practical Expedient, Remaining Performance Obligation, Description Revenue, practical expedient description Issuance of common stock under equity plans (in shares) Stock Issued During Period Shares Under Equity Plan Stock issued during period shares under equity plan. Revolving credit line available Line of Credit Facility, Current Borrowing Capacity Net Cash Provided by (Used in) Investing Activities Net cash used in investing activities Document Quarterly Report Document Quarterly Report Additional upfront payment. Additional Upfront Payment Additional payment Counterparty Name [Domain] Counterparty Name Security Deposit Security deposit Maximum potential upfront payment amount payable on termination of agreement. Maximum Potential Upfront Payment Amount Payable On Termination Of Agreement Maximum potential upfront payment amount payable Net cash (used in) provided by financing activities Net Cash Provided by (Used in) Financing Activities Entity Filer Category Entity Filer Category Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Non-cash investing activities Increase (Decrease) in Accrued Liabilities Accrued liabilities Increase (Decrease) in Accrued Liabilities, Total Variable Rate [Axis] Accrued Liabilities, Current [Abstract] Royalty payments. Royalty Payments Royalty payments Disbursement payment upon achievement of required manufacturing practices and IND application. Disbursement Payment Upon Achievement Of Required Manufacturing Practices And I N D Application Disbursement payment upon achievement of required manufacturing practices and IND application Purchase of property and equipment in accounts payable and accrued expenses Capital Expenditures Incurred but Not yet Paid Liabilities Total liabilities Property, Plant and Equipment [Table] Schedule Of Property Plant And Equipment [Table] Value added tax payable. Value Added Tax Payable Value added tax payable Equity, Attributable to Parent Balance Balance Total stockholders’ equity SOFR [Member] Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member] Net loss Net income (loss) Net income (loss) Net Income (Loss) Net loss Seqirus, Inc. Seqirus, Inc [Member] Seqirus, Inc [Member] Statement of Financial Position [Abstract] Diluted Weighted Average Number of Shares Outstanding, Diluted Weighted Average Number of Shares Outstanding, Diluted, Total ISRAEL Israeli Ministry of Health ("MOH") [Member] Acquisition of research and development in process through issuance of common stock. Acquisition Of Research And Development In Process Through Issuance Of Common Stock Acquisition of in-process research and development through issuance of common stock Investment Owned, Net Assets, Percentage Percentage of owned shares Grant receivable number of installments. Grant Receivable Number Of Installments Grant, number of installments Disbursement period one. Disbursement Period One [Member] Disbursement Due January 2020 [Member] Operating Lease, Weighted Average Remaining Lease Term Weighted-average remaining lease term Percentage of value added tax. Percentage Of Value Added Tax Percentage of value added tax Disbursement amount payable upon achievement of project goal. Disbursement Amount Payable Upon Achievement Of Project Goal Disbursement amount payable upon achievement of project goal Income Tax Disclosure [Text Block] Income Taxes Stock Issued During Period, Value, Issued for Services Common stock issued, value Grant two. Grant Two [Member] Grant 2 Debt instrument interest only payment extended period. Debt Instrument Interest Only Payment Extended Period Extension to interest only period Disaggregation of Revenue [Line Items] Disaggregation Of Revenue [Line Items] Leasehold Improvements [Member] Leasehold improvements [Member] Upfront payment payable. Upfront Payment Payable Upfront payment payable Fair Value Disclosures [Abstract] Axcelead, Inc. Axcelead Inc [Member] Axcelead, Inc [Member] Other collaboration agreements. Other Collaboration Agreements [Member] Other Collaboration Agreements [Member] Payments to Acquire Property, Plant, and Equipment Acquisition of property and equipment Payments to Acquire Property, Plant, and Equipment, Total Stock Issued During Period, Shares, New Issues Issuance of common stock, net of issuance costs (in shares) Issuance of common stock Employee-related Liabilities, Current Accrued compensation Employee-related Liabilities, Current, Total Deferred Revenue, Current Deferred revenue Deferred Revenue, Current, Total Interest Expense, Long-Term Debt Interest expense related to long-term debt Interest Expense, Long-term Debt, Total Income Tax Disclosure [Abstract] GRI Bio [Member] GRI Bio Inc Member GRI Bio Inc.